Feasibility study of chemotherapeutic efficacy assessment in hyperthermic intraperitoneal chemotherapy (HIPEC)

Le résumé fourni par la source

Abstract Purpose CRS-HIPEC serves as the primary treatment for peritoneal cancers. Although CRS-HIPEC frequently yields positive outcomes, some patients may experience a swift recurrence of cancer. Consequently, a technique to detect any remaining viable tumor cells post-treatment would be advantageous. We propose to explore the feasibility of employing flow cytometry to differentiate viable tumor cells following CRS-HIPEC treatment. Patients and methods During the CRS-HIPEC procedure, peritoneal fluid was collected at two distinct time points: pre-HIPEC perfusion and post-HIPEC. The cells were then concentrated. After in vitro culture, the cells underwent staining. In summary, anti-tumor marker antibodies were used to gate tumor cells. Apoptotic and viable cells were distinguished using Annexin V and Zombie dyes, respectively. Fluorescence minus one (FMO) control were implemented to establish gate boundaries, while unstained cells used as negative controls. A flow cytometer was used for data collection. Results This feasibility study encompassed six patients (with colorectal, colorectal, gastric, appendix, appendix, and peritoneum cancers, respectively) who underwent CRS-HIPEC between October and December 2023. Through this feasibility study, we demonstrated that evaluating the efficacy of HIPEC drug on pre- and post-HIPEC samples is achievable. The data indicated an increase in apoptotic cells by 30.6, 13.2, 12.8, 66.1, 3.9, and 8.1%, following HIPEC treatment with MMC, MMC, MMC & Cisplatin, Cisplatin, MMC, and Carboplatin, respectively. Conclusion This feasibility study offers initial insights into the capability of a flow cytometry approach to identify and differentiate viable tumor cells from apoptotic and necrotic cells in samples obtained from HIPEC patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.